Teewinot Life Sciences Corporation Interview

Teewinot Life Sciences is an international biopharmaceutical company employing its patent-protected CannSynthesis® technology to biosynthesize cannabinoids for the large-scale manufacture of pharmaceutically pure cannabinoids including the varin series of compounds, which are only found in relatively small quantities in the cannabis plant. Teewinot’s focus is on the biosynthetic production of pure, naturally-occurring cannabinoids, cannabinoid prodrugs and analog compounds by utilizing proprietary biocatalysis and synthetic biology for clinical development of FDA-approved pharmaceuticals. To date, Teewinot researchers have synthesized over 18 different naturally occurring cannabinoids in pharmaceutically pure form. The company employs its proprietary, disruptive technology to develop therapeutics for diseases identified as viable cannabinoid targets such as pain management, opioid addiction, oncology, psychiatric and central nervous system disorders, inflammation, and other drug development indications. Headquartered in Tampa, Florida, Teewinot is a global leader in the manufacturing and delivery of safe and standardized products containing cannabinoids, cannabinoid prodrugs, and cannabinoid analogs for diverse consumer markets. The company’s wholly owned subsidiaries in Ireland and Canada, along with collaborations formed with key research institutions, consumer product companies, manufacturers, and local communities, combine cutting-edge scientific research on cannabinoids with an aggressive intellectual property portfolio to create new and improved patient therapies.